AstraZeneca - Research-Based BioPharmaceutical Company

The 4 Ps of sustainable access to healthcare

Science is at the heart of everything we do.

What drives you today?

Ground-breaking science

There is an expanding universe of biological data available which can revolutionise our understanding of disease and therapy if we find innovative ways to share and explore it.
Principal Scientist, Bioinformatics, Oncology, IMED Biotech Unit

Go to our current Bioinformatics jobs

Publications

Our innovative science means a strong track-record of publication in peer-reviewed journals, contributing to the foundation of scientific advancement.

View our publications

We have

150

projects in our pipeline

View pipeline

Acoustic mass spectrometer platform

Explore our technology

Our Gothenburg (Sweden) site is one of AstraZeneca's three global strategic science centres

Explore all our science centres

Corporate Press Release

AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer

16 November 2018

Corporate Press Release

AstraZeneca to divest US Synagis rights to Sobi

13 November 2018

Our science

At AstraZeneca, science is at the core of everything we do. But more than that, science is who we are.

Find out more

Career opportunities

There is an expanding universe of biological data available which can revolutionise our understanding of disease and therapy if we find innovative ways to share and explore it.
Jonathan Dry, Principal Scientist, Bioinformatics, Oncology, Innovative Medicines & Early Development

Go to our current Bioinformatics jobs

Acoustic mass spectrometer platform

Explore our technology

Three

strategic science centres

Our research sites are collaborative, innovative and dynamic environments that allow our scientists to keep pushing the boundaries

Find our about our science

Inhibiting stages in the DNA damage response pathway

Our focus areas

Cardiovascular and Metabolic diseases

Oncology

Respiratory

Inflammation and autoimmunity

Neuroscience

Infection and Vaccines

AstraZeneca job search

At AstraZeneca we are guided in our work by a strong set of values, and we’re resetting expectations of what a bio-pharmaceutical company can be. If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.

Search for a job now

Start a career that will help improve life for millions.

Learn more about our School/College Student, Undergraduate, Graduate and Post Doctorate programmes with us in our Early Careers page.

Find your early career now

Working at AstraZeneca

We need great people who share our passion for science and have the drive and determination to meet the unmet needs of patients around the world. Find out more about our teams and the work they do.

Find out more on the careers section

To partner with AstraZeneca

I often say being in Business Development is having the best job in AstraZeneca in terms of the motivation, interest and challenging work we do with incredibly smart people from science and business on projects that really make a difference for our partners and patients.
Shaun Grady, Vice-President Business Development Operations

See our partnering contacts

Horizon Discovery and AstraZeneca: searching for novel, personalised cancer therapies

See more partnering case studies

Partnering with us

We partner with like-minded organisations and pursue a range of different types of opportunities that are aligned with our portfolio and areas of expertise.

Learn more about our areas of interest

Open Innovation

Our Open Innovation platform is designed to foster open innovation partnerships spanning all stages of drug discovery and development.

Learn more on the Open Innovation site

Corporate Press Release

US FDA accepts regulatory submission for Lynparza maintenance therapy in newly-diagnosed, BRCA-mutated advanced ovarian cancer and grants Priority Review

12 November 2018

Corporate Press Release

Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)

30 October 2018

Collaborate with us

The best science doesn't happen in isolation.

Visit our partnering section

Investor information

"Today marks an important day for the future of AstraZeneca, with the performance in the quarter and year to date showing what we expect will be the start of a period of sustained growth for years to come. Commercial execution has been exceptional and our new medicines are now firmly established as the drivers of growth, supporting our continued success in Emerging Markets. These new medicines are showing great promise, including Tagrisso, Imfinzi, Lynparza in cancer, Farxiga in diabetes and Fasenra in severe asthma. We’re also continuing to replenish our early-stage pipeline as we bring our innovative medicines to patients around the world."
Pascal Soriot, Executive Director and Chief Executive Officer

Meet our people

Latest presentation

Year-To-Date and Q3 2018 results

View quarterly results

Financial calendar

Find all the latest dates for ex-dividends, investor roadshows and more

See all key dates

LATEST FINANCIAL INFORMATION

See all the results and presentations

Read the latest Annual Report (2017)

Stock exchange announcements

Find all the latest announcements from the stock exchange

View latest announcements

Corporate Press Release

AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer

16 November 2018

Corporate Press Release

AstraZeneca to divest US Synagis rights to Sobi

13 November 2018

Investors

Find out more about investing in AstraZeneca, everything from investor relations to dividend policies.

Visit our investor relations